MetaCap

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)

NASDAQ: QNTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.29-0.13 (-9.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QNTM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.42
52-week range
1.26 – 12.42
Day range
1.26 – 1.41
Volume / Avg
140.26K / 148.83K
Beta
—

52-week range

$1.26$12.42

QNTM stock today

Shares of Quantum Biopharma (QNTM) finished lower on Nov 20 at $1.29, a drop of 9.15% or $0.13 per share, versus the S&P 500's 3.70% decline. At this level, QNTM sits near the bottom of its 52-week range of $1.26 to $12.42: 89.6% below the high, set on Nov 28, 2025 and 2.4% above the low. QNTM is down 82.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.6%.

Quantum Biopharma has posted a net loss over the last twelve months (EPS of -$3.42), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Quantum Biopharma

Company profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Zeeshan Saeed
Headquarters
Toronto, ON

Financial highlights

Full financials
Quantum Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income———$-23.61M$-35.29M
EPS (diluted)—————

Analyst forecast

Forecast

Consensus

none

Avg. price target

$12.27+851.16%

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.06 vs —

QNTM news

All QNTM news

Quantum Biopharma peers

Health Care sector
QNTM peer companies
CompanyPrice% ChgMarket capCompare
MBRXMoleculin Biotech Inc.7.74-2.40%$8.22Mvs QNTM
HINDVyome Holdings Inc.1.20-17.24%$8.42Mvs QNTM
PTNPalatin Technologies Inc.4.58-7.10%$8.16Mvs QNTM
LEXXLexaria Bioscience Corp.4.03-10.24%$8.49Mvs QNTM
DAREDare Bioscience Inc.0.4074-9.87%$8.01Mvs QNTM
BIVIBioVie Inc. Class A0.80-12.07%$8.58Mvs QNTM
CLRBCellectar Biosciences Inc.0.797-11.50%$8.00Mvs QNTM
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs QNTM

Indexes, lists and sector

Quantum Biopharma stock FAQ

What is Quantum Biopharma's stock price today?

QNTM last traded at $1.29 as of Nov 20, 4:00 PM EST, down 9.15% on the day. Prices are delayed at least 15 minutes.

Does Quantum Biopharma pay a dividend?

No. Quantum Biopharma does not currently pay a regular cash dividend.

Who is Quantum Biopharma's CEO?

Mr. Zeeshan Saeed is the chief executive officer of Quantum Biopharma Ltd. Class B Subordinate Voting Shares.

Has QNTM ever split its stock?

Yes. The most recent QNTM stock split was a 1-for-65 split on Aug 15, 2024, one of 2 splits on record.

What is the QNTM 52-week high?

The 52-week high for QNTM is $12.42 and the 52-week low is $1.26. The stock is currently 89.6% below its high.

Compare QNTM